

## RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE

### Previous fracture and subsequent fracture risk

WHI program; Beaudart, C.

*Published in:*  
Osteoporosis International

*DOI:*  
[10.1007/s00198-023-06870-z](https://doi.org/10.1007/s00198-023-06870-z)

*Publication date:*  
2023

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication](#)

*Citation for published version (HARVARD):*  
WHI program & Beaudart, C 2023, 'Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX', *Osteoporosis International*, vol. 34, no. 12, pp. 2027-2045. <https://doi.org/10.1007/s00198-023-06870-z>

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

### Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



# Previous fracture and subsequent fracture risk: a meta-analysis to update FRAX

J.A. Kanis<sup>1,2</sup> · H. Johansson<sup>1,3</sup> · E.V. McCloskey<sup>2,4</sup> · E. Liu<sup>1</sup> · K.E. Åkesson<sup>5,6</sup> · F.A. Anderson<sup>7</sup> · R. Azagra<sup>8,9,10</sup> · C.L. Bager<sup>11</sup> · C. Beaudart<sup>12,13</sup> · H.A. Bischoff-Ferrari<sup>14,15</sup> · E. Biver<sup>16</sup> · O. Bruyère<sup>12</sup> · J.A. Cauley<sup>17</sup> · J.R. Center<sup>18,19,20</sup> · R. Chapurlat<sup>21</sup> · C. Christiansen<sup>11</sup> · C. Cooper<sup>22,23,24</sup> · C.J. Crandall<sup>25</sup> · S.R. Cummings<sup>26</sup> · J.A.P. da Silva<sup>27,28</sup> · B. Dawson-Hughes<sup>29</sup> · A. Diez-Perez<sup>30</sup> · A.B. Dufour<sup>31,32</sup> · J.A. Eisman<sup>18,19,20</sup> · P.J.M. Elders<sup>33</sup> · S. Ferrari<sup>16</sup> · Y. Fujita<sup>34</sup> · S. Fujiwara<sup>35</sup> · C.-C. Glüer<sup>36</sup> · I. Goldshtein<sup>37,38</sup> · D. Goltzman<sup>39</sup> · V. Gudnason<sup>40,41</sup> · J. Hall<sup>42</sup> · D. Hans<sup>43</sup> · M. Hoff<sup>44,45</sup> · R.J. Hollick<sup>46</sup> · M. Huisman<sup>47,48</sup> · M. Iki<sup>49</sup> · S. Ish-Shalom<sup>50</sup> · G. Jones<sup>51</sup> · M.K. Karlsson<sup>5,6</sup> · S. Khosla<sup>52</sup> · D.P. Kiel<sup>31,32</sup> · W.-P. Koh<sup>53,54</sup> · F. Koromani<sup>55,56</sup> · M.A. Kotowicz<sup>57,58,59</sup> · H. Kröger<sup>60,61</sup> · T. Kwok<sup>62,63</sup> · O. Lamy<sup>64,65</sup> · A. Langhammer<sup>66</sup> · B. Larijani<sup>67</sup> · K. Lippuner<sup>68</sup> · D. Mellström<sup>69,70</sup> · T. Merlijn<sup>71</sup> · A. Nordström<sup>72,73,74</sup> · P. Nordström<sup>75</sup> · T.W. O'Neill<sup>76,77</sup> · B. Obermayer-Pietsch<sup>78,79</sup> · C. Ohlsson<sup>80,81</sup> · E.S. Orwoll<sup>82</sup> · J.A. Pasco<sup>57,58,59,83</sup> · F. Rivadeneira<sup>55</sup> · A.-M. Schott<sup>84</sup> · E.J. Shiroma<sup>85</sup> · K. Siggeirsdottir<sup>40,86</sup> · E.M. Simonsick<sup>87</sup> · E. Sornay-Rendu<sup>88</sup> · R. Sund<sup>61</sup> · K.M.A. Swart<sup>33,89</sup> · P. Szulc<sup>88</sup> · J. Tamaki<sup>90</sup> · D.J. Torgerson<sup>91</sup> · N.M. van Schoor<sup>47</sup> · T.P. van Staa<sup>92</sup> · J. Vila<sup>93</sup> · N.J. Wareham<sup>94</sup> · N.C. Wright<sup>95</sup> · N. Yoshimura<sup>96</sup> · M.C. Zillikens<sup>55</sup> · M. Zwart<sup>10,97,98,99</sup> · L. Vandenput<sup>1,80</sup> · N.C. Harvey<sup>22,23</sup> · M. Lorentzon<sup>1,3</sup> · W.D. Leslie<sup>100</sup>

Received: 22 March 2023 / Accepted: 22 July 2023

© International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation 2023

## Abstract

**Summary** A large international meta-analysis using primary data from 64 cohorts has quantified the increased risk of fracture associated with a previous history of fracture for future use in FRAX.

**Introduction** The aim of this study was to quantify the fracture risk associated with a prior fracture on an international basis and to explore the relationship of this risk with age, sex, time since baseline and bone mineral density (BMD).

**Methods** We studied 665,971 men and 1,438,535 women from 64 cohorts in 32 countries followed for a total of 19.5 million person-years. The effect of a prior history of fracture on the risk of any clinical fracture, any osteoporotic fracture, major osteoporotic fracture, and hip fracture alone was examined using an extended Poisson model in each cohort. Covariates examined were age, sex, BMD, and duration of follow-up. The results of the different studies were merged by using the weighted  $\beta$ -coefficients.

**Results** A previous fracture history, compared with individuals without a prior fracture, was associated with a significantly increased risk of any clinical fracture (hazard ratio, HR = 1.88; 95% CI = 1.72–2.07). The risk ratio was similar for the outcome of osteoporotic fracture (HR = 1.87; 95% CI = 1.69–2.07), major osteoporotic fracture (HR = 1.83; 95% CI = 1.63–2.06), or for hip fracture (HR = 1.82; 95% CI = 1.62–2.06). There was no significant difference in risk ratio between men and women. Subsequent fracture risk was marginally downward adjusted when account was taken of BMD. Low BMD explained a minority of the risk for any clinical fracture (14%), osteoporotic fracture (17%), and for hip fracture (33%). The risk ratio for all fracture outcomes related to prior fracture decreased significantly with adjustment for age and time since baseline examination.

**Conclusion** A previous history of fracture confers an increased risk of fracture of substantial importance beyond that explained by BMD. The effect is similar in men and women. Its quantitation on an international basis permits the more accurate use of this risk factor in case finding strategies.

**Keywords** Hip fracture · Major osteoporotic fracture · Meta-analysis · Osteoporotic fracture · Prior fracture

Extended author information available on the last page of the article

## Introduction

A history of a prior fracture at a site characteristic for osteoporosis is an important risk factor for further fracture [1–6]. Fracture risk is approximately doubled in the presence of a prior fracture, including morphometric vertebral fractures. The risks are in part independent of BMD [4]. However, the increase in risk is not constant with age. For example, a large meta-analysis showed that a prior fracture history was a significant risk factor for hip fracture at all ages, but the population relative risk was highest at younger ages and decreased progressively with age [4].

The identification of patients with a fracture history is a well-established goal in the clinical management of osteoporosis as outlined in most clinical guidelines worldwide [7–12]. In many cases, individuals with a prior fracture are eligible for treatment irrespective of BMD. For example, the National Osteoporosis Guideline Group (NOGG) in the UK recommends treatment in all women with a prior fragility fracture [10]. A similar threshold is provided in the European guidance [13]. In the USA, a prior vertebral or hip fracture qualifies for a treatment recommendation irrespective of BMD [14].

Because a prior fracture provides a fracture risk that is largely independent of BMD, it has been incorporated into assessment guidelines that integrate the risks associated with a number of risk variables [15–17]. FRAX®, currently available in 78 territories, is the most widely used fracture risk assessment tool and is incorporated into a large number of assessment guidelines [7], recommended by the Committee for Medicinal Products for Human Use (CHMP) [18], and approved by the National Institute for Health and Care Excellence (NICE) [19]. The incorporation of a prior fracture as an input variable for risk prediction was based on a meta-analysis, published in 2004, of 15,259 men and 44,902 women from 11 cohorts followed for a total of 250,000 person-years [4]. Since then, many more prospectively studied cohorts have become available that have the potential to improve the accuracy of FRAX [20].

The aim of the present study was to quantify the risk for future fracture associated with a history of prior fracture in an international setting and to explore the dependence of this risk on age, sex, time since baseline assessment and BMD.

## Methods

The study population was derived from a systematic review that identified prospective cohort studies for the update of FRAX. The study was registered with the

International prospective register of systematic reviews, PROSPERO (CRD42021227266), and followed the Preferred Reporting Items for Systematic Reviews (PRISMA) guidelines. Studies were eligible if the cohort was prospective, included at least 200 participants, assessed an adequate number of clinical risk factors, and reported an adequate number of incident fracture outcomes. We studied 2,104,506 men and women from 64 prospectively studied cohorts of whom 9.7% had a prior fracture history. Fifty-eight cohorts included women ( $n = 1,438,535$ ) and 40 cohorts included men ( $n = 665,971$ ). Details of the cohorts studied have been given previously [20] and are summarized in Table 1.

## Baseline and outcome variables

The construct of the question to determine a prior fracture history differed between the cohorts studied, based on time of previous fracture, fracture site, energy, validity, and inclusion of morphometric vertebral fractures (Table 2).

For outcomes, information on all clinical fractures was used for this report “all fractures.” In addition, fractures considered to be associated with osteoporosis were examined [21]. According to this classification, fractures of the skull, face, hands, feet, ankle, and patella were excluded as well as tibial and fibular fractures in men. Hip fracture and major osteoporotic fracture were also analyzed separately. No distinction was made according to trauma since both high- and low-trauma fractures show similar relationships with low BMD and future fracture risk [22]. The risk of death as function of fracture history was also assessed.

## Statistical methods

The risk of fracture was estimated by an extended Poisson model applied separately to each cohort (and also separately by sex for those cohorts with both men and women) [23, 24]. Because of an embargo on transfer of primary data from Manitoba, Cox regression was used on the Manitoba cohort on site and beta-coefficients, variances, and covariances forwarded to the analysis team. Covariates included current time since start of follow-up, current age (derived from age at start of follow-up and current time since start of follow-up), prior history of fracture, and BMD at the femoral neck. Femoral neck BMD was adjusted for manufacturer and T-scores were calculated from the NHANES III White female reference values [20]. We additionally estimated a model that excluded BMD from the covariates. A further model included the interaction term “prior fracture· current time since baseline” to determine whether the strength of the association of prior fracture and fracture risk changed with time. An additional model included the interaction term “prior fracture· current age” to determine whether the

**Table 1** Characteristics of the cohorts studied

Cohort	Quality grade	n	Person years	Age (years)		% female	Prior fracture (%)	Number of fractures				Osteoporotic
				Mean	Range			Hip	Any	MOF	MOF minus hip	
AGES	A	5706	45,508	77.0	66–98	57.6	42.2	535	1619	1134	766	1395
AHS	B	2613	10,109	65.1	47–95	69.6	25.9	32	368	281	257	281
APOSS	A	3840	33,629	48.5	44–56	100	13.1	4	335	142	141	176
AUSTRIOS B	C	2046	2370	83.9	68–103	84.1	46.6	76	174	-	-	-
BEH	B	2414	10,085	69.3	60–96	51.9	12.9	42	105	-	-	-
Bern	B	23,104	181,352	58.9	20–95	85.0	43.9	294	5033	2913	2730	3891
CaMos	A	9422	121,627	62.1	25–103	69.4	44.0	340	2435	1188	935	1753
DO_HEALTH	B	2139	5914	75.0	70–95	61.9	22.5	10	264	118	111	190
DOES	A	2133	18,884	70.1	47–94	60.7	15.0	110	561	363	294	465
ECOSAP	B	5146	16,857	72.3	65–100	100	20.2	52	311	188	136	259
EPIC-Norfolk	A	25,600	493,500	59.2	39–79	54.7	7.0	1356	3040	2344	1205	-
EPIDOS	B	7595	21,192	80.5	70–100	100	45.0	226	1026	568	376	837
EPIFROS	B	284	2826	61.6	40–96	54.6	4.6	3	27	16	13	20
EVOS/EPOS	B	13,366	40,983	63.8	41–91	52.1	36.3	44	538	286	245	538
FORMEN	A	1885	16,253	72.5	65–93	0	7.9	10	90	58	49	90
Framingham offspring	A	3539	58,402	61.5	33–90	54.1	33.9	105	758	316	239	533
Framingham original	A	1166	11,184	79.9	72–101	65.3	20.0	136	279	187	68	242
FRIDEX	B	815	8077	56.8	40–84	100	20.4	15	112	41	28	56
PROCAT	A	1953	19,404	69.2	32–111	55.7	17.1	33	229	160	135	183
GERICO	C	764	2766	67.9	65–72	79.5	46.3	2	71	26	24	51
GLOW	B	54,258	216,703	68.2	55–108	100	3.1	490	5690	2848	2437	4285
GOS	A	1403	9364	69.5	50–95	100	30.3	31	149	105	80	135
Gothenburg I	A	1736	9818	85.5	70–96	57.0	10.7	304	431	361	100	408
Gothenburg II	A	11,371	149,825	59.0	21–84	100	16.8	259	1192	739	644	856
HAI	B	2085	3303	70.5	70–72	51.1	14.1	4	42	26	22	36
HCS	A	632	5595	64.9	59–71	50.3	16.3	3	67	35	33	51
Health ABC	A	3062	36,309	73.6	68–80	51.5	22.0	235	696	518	349	594
HUNT	A	50,209	622,020	53.2	20–100	54.6	23.4	1674	10,239	4733	3601	7128
JPOS	B	1944	25,812	57.5	40–82	100	15.8	29	265	99	-	-
LASA	A	1473	7575	75.7	65–89	51.6	27.9	38	131	-	-	95
Maccabi	A	659,266	6,297,325	56.3	30–91	52.0	4.8	11,293	54,312	51,955	42,759	53,907
Manitoba	B	92,281	833,424	63.4	20–104	89.1	21.3	3085	13,506	9578	7187	12,655

Table 1 (continued)

Cohort	Quality grade	n	Person years	Age (years)		% female	Prior fracture (%)	Number of fractures				Osteoporotic
				Mean	Range			Hip	Any	MOF	MOF minus hip	
MINOS	B	681	6152	65.2	50–86	0	12.8	3	63	25	22	56
Miyama	A	400	3703	59.1	40–79	50.0	33.5	7	61	35	30	47
MrOS Hong Kong	B	2000	19,744	72.4	65–92	0	13.7	63	231	148	93	201
MrOS Sweden	A	2999	34,019	74.9	69–81	0	20.9	339	968	728	482	874
MrOS USA	A	5993	74,998	73.7	64–100	0	55.3	330	1394	814	490	1082
MsOS Hong Kong	B	2000	17,528	72.6	65–98	100	20.8	69	338	247	189	298
NHEFS	A	12,206	121,623	49.4	25–74	59.6	6.7	113	-	-	-	-
OFELY	A	867	15,136	58.8	40–89	100	10.3	40	245	180	159	207
OPRA	A	1044	12,133	75.2	75–76	100	45.8	195	524	453	-	473
OPUS	B	1983	12,167	62.0	20–80	100	42.0	14	236	113	102	148
OsteoLaus	B	1475	6726	64.5	50–82	100	36.4	8	307	226	221	245
OSTPRE	B	11,200	109,465	57.3	52–62	100	9.0	80	1851	918	848	1259
PERF	B	5760	37,802	64.2	44–81	100	17.3	62	828	544	489	550
REFORM	C	1003	1483	77.9	65–99	60.5	6.5	4	30	12	8	17
Rochester	A	1001	7686	56.8	21–94	65.2	18.1	37	326	243	229	283
Rotterdam	A	14,619	158,085	65.8	45–106	58.8	22.9	830	3317	2322	1742	2892
SAOL_IPR_EPIPorto	B	929	11,284	55.9	40–89	77.4	12.7	12	105	9	-	-
SarcoPhAge	C	228	440	75.9	68–93	57.0	25.4	1	13	5	4	8
SCHS	A	52,042	462,436	61.6	48–84	57.4	8.1	1091	-	-	-	-
SCOOP	A	12,368	58,826	75.6	70–86	100	23.1	378	1927	1284	975	1625
SEMOF	B	7130	20624	75.2	70–91	100	51.7	80	683	464	384	596
Sheffield	B	2148	7354	80.0	74–101	100	45.4	66	281	186	132	227
SOF	B	9619	135,474	71.6	65–89	100	37.1	1404	4337	2794	1833	3455
SOS	B	16,626	62,119	74.2	61–92	100	30.0	260	1383	993	702	1325
STOP/IT	B	424	1840	71.1	65–87	55.0	49.1	2	50	24	22	32
STRAMBO	A	823	7582	72.1	51–88	0	11.7	17	117	42	26	86
SUPERB	B	3019	10,736	77.8	75–81	100	36.8	70	463	341	-	421
TASOAC	B	1098	10,955	63.0	51–81	48.9	44.2	5	146	49	46	88
THIN	A	366,104	2,125,764	63.8	50–116	100	9.1	6942	31,633	-	-	23,622
UK Biobank	B	502,536	5,766,212	56.5	37–73	54.4	3.7	3943	25,190	12,099	8332	20,075
WHI	B	64,399	868,380	65.8	55–79	100	17.4	1981	5259	3712	1901	4213
York	B	4532	9044	77.1	48–99	100	44.7	42	393	223	189	310

Table 1 (continued)

Cohort	Quality grade	n	Person years	Age (years)		% female	Prior fracture (%)	Number of fractures				Osteoporotic
				Mean	Range			Hip	Any	MOF	MOF minus hip	
Total		2,104,506	19,535,515	61.5	20–116	68.3	9.7	39,358	186,794	110,559	84,614	155,825 <sup>a</sup>
Mean												

MOF major osteoporotic fracture, AGES Age, Gene/Environment Susceptibility-Reykjavik Study, AHS Adult Health Study, APOSS Aberdeen Prospective Osteoporosis Screening Study, BEH Bushehr Elderly Health, CaMos Canadian Multicentre Osteoporosis Study, DOES Dubbo Osteoporosis Epidemiology Study, DO-HEALTH VitaminD3-Omega3-Home Exercise-Healthy Aging and Longevity Trial, ECOSAP Ecografía Osea en Atención Primaria, EPIC-Norfolk European Prospective Investigation of Cancer-Norfolk, EPIDOS Epidemiologie de l'Ostéoporose, EPiFROS EPidemiology and Fracture Risk factors for Osteoporosis in Spain, EVOS/EPOS European Vertebral Osteoporosis Study/European Prospective Osteoporosis Study, FORMEN Fujiwara-kyo Osteoporosis Risk in Men, FRIDEX Fracture Risk factors and bone Densitometry type central dual X-ray, FROCAT Fracture Risk factors for Osteoporosis in Catalonia, GERICO Geneva Retirees Cohort, GLOW Global Longitudinal Study of Osteoporosis in Women, GOS Geelong Osteoporosis Study, HAI Healthy Ageing Initiative, HCS Hertfordshire Cohort Study, Health ABC Health, Aging and Body Composition, HUNT The Trøndelag Health Study, JPOS Japanese Population-based Osteoporosis Study, LASA Longitudinal Aging Study Amsterdam, MINOS Montceau les Mines Osteoporosis, MrOS Osteoporotic Fractures in Men, MrOS Osteoporotic Fractures in Women, NHEFS National Health and Nutrition Examination Survey (NHANES) I Epidemiologic Follow-up Study, OFELY Os des Femmes de Lyon, OPRA, Osteoporosis Prospective Risk Assessment, OPUS Osteoporosis and Ultrasound Study, OSTPRE Kuopio Osteoporosis risk factor and PREvention study, PERF Prospective Epidemiologic Risk Factor, REFORM Reducing Falls with ORtheses and a Multifaceted podiatry intervention, SAOL-IPR-EPiPorto Santo António dos Olivais, Instituto Português de Reumatologia and EPiPorto, SarcoPhAge Sarcopenia and Physical Impairment with advancing Age, SCHS Singapore Chinese Health Study, SCOOP screening for prevention of fractures in older women, SEMOF Swiss Evaluation of the Methods of Measurement of Osteoporotic Fracture risk, SOF Study of Osteoporotic Fractures, SOS SALT Osteoporosis Study, STRAMBO Structure of the Aging Men's Bone, SUPERB Sahlgrenska University hospital Prospective Evaluation of Risk of Bone fractures, TASOAC Tasmanian Older Adult Cohort, THIN The Health Improvement Network, WHI Women's Health Initiative

strength of the association of prior fracture and fracture risk changed with age. Interactions with time and with age were also explored using piece-wise linear regression to check the adequacy of the Poisson model. The hazard ratio (HR) for previous fracture was determined for each age from 40 years from the Poisson model. Results of each cohort and the two sexes were weighted according to the variance and merged to determine the weighted means and standard deviations. The HR of those with a prior fracture history versus those without a prior fracture history was equal to  $e^{\text{weighted mean of } \beta}$ . There was significant heterogeneity in risk between cohorts (index of heterogeneity  $I^2 = 82\text{--}98\%$  depending on fracture outcome), and a random effects model was used in the meta-analysis.

The component of the risk ratio explained by BMD was computed from a meta-analysis of BMD and fracture risk in men and women combined [25]. Based on the prior evidence, the risk of any clinical fracture was assumed to increase 1.45-fold for each SD decrease in BMD at the femoral neck. For hip fracture, the gradient of risk was assumed to be 2.07 per SD and 1.55 for any osteoporotic fracture [4]. These findings permitted comparison of the calculated expected difference in mean BMD between those with, versus those without, a prior fracture, with the actual difference ascertained from the baseline data. Thus, the proportion of risk attributed to a low BMD was computed as

$$\frac{[\log HR_a / \log GR] - [\log HR_b / \log GR]}{[\log HR_a / \log GR]}$$

where  $HR_a$  is the unadjusted hazard ratio for prior fracture,  $HR_b$  is the hazard ratio adjusted for BMD, and GR is the gradient of risk for femoral neck BMD [4].

Individuals with missing data were excluded. No data were imputed.

## Sensitivity analyses

As noted above, the effect of sex on the hazard ratio for fracture was examined in those cohorts that contributed both men and women. Similarly, differences in risk with and without BMD were additionally explored in those cohorts that contributed both scenarios. Assessment of the effects of race and ethnicity was confined to those cohorts recording more than one race or ethnic group (Asian, Black, Hispanic, White), comprising Health ABC, CAMOS, MROs USA, WHI, SOF, Manitoba, and UK Biobank. Results were also computed according to study quality as previously defined [20]. Quality was based on a 0/1 score for four criteria: population-based cohort (yes scores 1); fracture ascertainment (self-report scores 0, others score 1); duration of follow-up (> 2 years, scores 1); average loss to follow-up/year (< 10%, scores 1). This gives a maximum score of 4 and a minimum

**Table 2** Details of the construct of the questionnaire on fracture type and history in the cohorts studied

Element	Construct
Time horizon	Ever in life, adult life, from age 18, 20, 35, 40, 45, 50, past 12 months, 5 years or 10 years
Site of fracture	Any fracture, osteoporotic fracture, MOF
Energy	All trauma included, moderate trauma, low trauma
Validity	Self-reported, verified, based on GP medical record, administrative healthcare data, has a doctor/nurse/physician assistant told you?
Vertebral deformity	Vertebral fractures assessed by semiquantitative criteria included, not included

of 0. A quality score of 0 or 1 was designated as poor quality (designated C), a score of 2 or 3 categorized as intermediate quality (B), and a score of 4 designated as high quality (A). Quality grades are given in Table 1.

**Table 3** Prevalence of a prior fracture history in men and women by age. The Manitoba and Maccabi data are not included since primary data were not available

Age (years)	Fracture history (%)		
	Men	Women	Combined
40–49	4.2	3.5	3.8
50–59	5.9	7.0	6.6
60–69	6.4	11.0	9.6
70–79	14.1	20.6	19.3
80–89	17.8	23.7	22.7
90+	21.4	21.8	21.8

## Results

Of 2,104,506 men and women studied in 32 countries, 45,059 men and 158,659 women had sustained a prior fracture. At follow-up, 38,897 men and 147,897 women were identified as having a subsequent clinical fracture of any kind; 31,686 and 124,139 were characterized as osteoporotic in men and women, respectively; 26,744 men and 83,815 women sustained a MOF; 8182 and 31,176 were hip fractures. The total follow-up time was 6.8 million person years in men and 12.7 million person years in women. BMD measurements were available in 13.8% (289,841) of individuals. The probability of fracture history rose almost linearly with age from the age of 40 years but tended to decline in women after age 90 years (Table 3). The prevalence of recording a history of a prior fracture was higher in women than in men (OR = 1.34; 95% CI = 1.32–1.35 unadjusted).

**Table 4** Hazard ratio (HR) and 95% confidence interval (CI) of fracture at the sites indicated associated with a history of prior fracture in men and women and both sexes combined. HRs are adjusted for age and time since baseline

	Outcome fracture	Number of cohorts	I <sup>2</sup> (%)	HR	95% CI
<b>Women</b>					
	Any	56	94	1.84	1.72–1.97
	Hip	51	81	1.71	1.57–1.86
	MOF	50	94	1.77	1.63–1.93
	MOF without hip fracture	45	91	1.80	1.65–1.95
	Osteoporotic	51	94	1.82	1.70–1.96
<b>Men</b>					
	Any	34	97	1.92	1.56–2.34
	Hip	29	91	1.99	1.53–2.59
	MOF	31	96	1.90	1.51–2.39
	MOF without hip fracture	30	94	1.79	1.43–2.25
	Osteoporotic	31	97	1.92	1.55–2.38
<b>Men and women</b>					
	Any	62	98	1.85	1.69–2.02
	Hip	56	92	1.77	1.59–1.98
	MOF	55	97	1.80	1.61–2.01
	MOF without hip fracture	51	96	1.80	1.62–2.01
	Osteoporotic	56	98	1.84	1.68–2.03



## Risk of fracture by site and sex


Previous fracture was associated with a significantly increased risk of any subsequent fracture (Table 4). In men and women, the HR ranged from 1.71 to 1.99 depending upon category of the outcome fracture. There were no significant differences in hazard ratios by site of fracture. The risk ratio was marginally but not significantly higher in men than in women by approximately 7–11%. In a sensitivity analysis using only those cohorts that contributed both men and women, there was no sex difference in hazard ratio for all sites (Appendix, Table A)

The increase in risk among those who reported a prior clinical fracture was fairly heterogeneous as shown in the forest plots in Fig. 1 for MOF and hip fracture outcomes. Forest plots for any clinical fracture and osteoporotic fracture outcomes are given in the Appendix. Heterogeneity was not

related to the question construct since the question construct had little effect on the outcome. In the case of an osteoporotic fracture, for example, the question construct of any prior fracture was associated with a similar increase in fracture risk ( $HR = 1.87$ ;  $95\%CI = 1.58$ – $2.22$ ) as that when the question referred to a prior major osteoporotic fracture ( $HR = 1.77$ ;  $95\%CI = 1.51$ – $2.07$ ) or where the site of prior fracture was unspecified ( $HR = 1.75$ ;  $95\%CI = 1.61$ – $1.89$ ). Similarly, there was no significant difference when low or moderate trauma was specified ( $HR = 1.77$ ;  $95\%CI = 1.41$ – $2.22$ ) or unspecified ( $HR = 1.84$ ;  $95\%CI = 1.67$ – $2.03$ ;  $p > 0.3$ ).

## Dependence on BMD

The impact of BMD on the fracture risk in individuals with a prior fracture is quantified in Table 5. The HR



**Fig. 1** Forest plot showing effect size on hip fracture risk (left panel) and major osteoporotic fracture (right panel) associated with a prior fracture in men and women combined adjusted for age and time since baseline



**Table 5** Hazard ratio (HR) and 95% confidence interval (CI) of fracture at the sites indicated associated with a history of prior fracture in men and women combined. HRs are adjusted for age and time since

baseline and additionally adjusted for BMD where indicated. The last column indicates the proportion of risk explained by BMD

Outcome fracture	Number of cohorts	Unadjusted		Adjusted for BMD		Gradient of risk (HR/SD) for BMD	Proportion of risk (%) from BMD
		HR	95% CI	HR	(95% CI)		
Any	52	1.79	1.67–1.92	1.65	1.53–1.78	1.45	14
Hip	45	1.70	1.58–1.84	1.43	1.30–1.56	2.07	33
Osteoporotic	48	1.78	1.65–1.92	1.61	1.48–1.75	1.55	17

was marginally decreased by approximately 8–16% when account was taken of BMD. In the case of any clinical fracture, if it is assumed that the risk of any clinical fracture increases 1.45-fold for each standard deviation (SD) decrease in hip BMD (gradient of risk), then the difference in risk between those with and without a prior fracture is equal to an expected difference in BMD of 1.57SD [ $\log 1.79/\log 1.45$ ]. In reality, the difference in BMD at all ages in men and women combined was approximately 0.22 SD ( $[\log(1.79)/\log(1.45)] - [\log(1.65)/\log(1.45)]$ ). Thus, low BMD accounted for the minority (14%;  $0.22/1.57$ ) of the difference in risk of any clinical fracture between those with or without a prior fracture. As would be expected, the proportion of risk accounted for by BMD was greater in the case of hip fractures (see Table 5) but remained less than 50% (see Table 5).

### Interaction with age

A prior fracture history was a significant risk factor for fracture at all ages. The hazard ratio was highest at younger

ages and decreased progressively with age (Table 6). The interaction term was significant for all fracture outcomes in men and women combined. The decrease with age was most marked for hip fracture which decreased by approximately 16% for each decade of age (Fig. 2). An almost identical relationship was observed using piece-wise linear regression (data not shown).

### Interaction with time

Fracture risk associated with a prior fracture decreased slowly with time since baseline by about 2–4% per year (Table 7). A similar relationship was observed using piece-wise linear regression (data not shown).


### Race and ethnicity

With one exception, there was no difference in the HR by race and ethnicity in those cohorts where race or ethnicity

**Table 6** Hazard ratio (HR) and 95% confidence interval (CI) of fracture by age at baseline at the sites indicated associated with a history of prior fracture in men and women combined. HRs are adjusted for time since baseline and sex. *n* refers to the number of cohorts available. *P* values refer to the significance of the interaction term with age

Age (years)	Site of outcome fracture							
	Any ( <i>n</i> = 62)		Hip ( <i>n</i> = 56)		MOF ( <i>n</i> = 55)		Osteoporotic ( <i>n</i> = 56)	
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
40	2.47	1.96–3.13	3.57	2.42–5.27	2.32	1.77–3.03	2.40	1.87–3.08
45	2.38	1.93–2.94	3.27	2.30–4.67	2.22	1.74–2.84	2.31	1.84–2.89
50	2.29	1.90–2.76	3.00	2.18–4.13	2.13	1.71–2.66	2.22	1.82–2.72
55	2.20	1.87–2.59	2.76	2.08–3.66	2.05	1.68–2.49	2.14	1.79–2.55
60	2.11	1.84–2.43	2.53	1.98–3.24	1.97	1.66–2.33	2.06	1.76–2.40
65	2.03	1.81–2.28	2.32	1.88–2.86	1.89	1.63–2.19	1.98	1.73–2.25
70	1.96	1.78–2.15	2.13	1.78–2.54	1.81	1.60–2.05	1.90	1.71–2.12
75	1.88	1.75–2.02	1.95	1.70–2.25	1.74	1.57–1.92	1.83	1.68–1.99
80	1.81	1.72–1.90	1.79	1.61–1.99	1.67	1.55–1.80	1.76	1.65–1.88
85	1.74	1.68–1.80	1.64	1.52–1.77	1.60	1.52–1.69	1.69	1.62–1.77
90	1.67	1.63–1.72	1.51	1.43–1.59	1.54	1.49–1.59	1.63	1.58–1.68
	<b><i>P</i> = 0.0014</b>		<b><i>P</i> &lt; 0.001</b>		<b><i>P</i> = 0.0011</b>		<b><i>P</i> = 0.0013</b>	

**Fig. 2** Hazard ratio (HR) and 95% confidence interval of a major osteoporotic fracture (MOF) and hip fracture by age associated with a history of prior fracture in men and women combined. HRs are adjusted for time since baseline and sex



was documented (Table B of Appendix). The exception was for major osteoporotic fracture such that in Blacks, those with prior fracture history had a higher risk of subsequent fracture hazard ratio than Whites (Blacks: HR = 2.43, 95% CI = 1.37–3.78 vs. Whites: HR = 1.57, 95% CI = 1.32–1.87). The effect was largely driven by a high HR in Blacks from Manitoba (HR = 5.34, 95% CI = 1.79–15.94) Fig. 3.

### Quality scores

There was no significant difference in fracture outcomes when cohorts of high quality were compared with those of moderate quality (Appendix, Table C). For cohorts of low quality, there was a significant difference from high-quality cohorts for MOF, based on a single low-quality cohort (GERICO).

### Risk of death

A prior fracture was associated with a significant increase in the risk of death in both men (HR = 1.11; 95%CI = 1.02, 1.21) and women (HR = 1.10; 95%CI = 1.05–1.15). Hazard ratios remained unchanged when adjusted for femoral neck BMD.

### Discussion

The present study represents the largest meta-analysis to date on the association between prior fracture and subsequent fracture risk. The effect is similar in men and women and is consistent with our previous meta-analyses

**Table 7** Hazard ratio (HR) and 95% confidence interval (CI) of fracture by time since baseline at the sites indicated associated with a history of prior fracture in men and women combined. HRs are adjusted for age and sex. *N* refers to the number of cohorts available. *P* values refer to the significance of the interaction term with time since baseline

Time (years)	Site of outcome fracture							
	Any ( <i>n</i> = 61)		Hip ( <i>n</i> = 54)		MOF ( <i>n</i> = 54)		Osteoporotic ( <i>n</i> = 55)	
	HR	95% CI	HR	95% CI	HR	95% CI	HR	95% CI
0	2.12	1.78–2.52	2.12	1.73–2.69	2.06	1.65–2.57	2.13	1.76–2.58
1	2.06	1.76–2.41	2.04	1.70–2.55	2.00	1.63–2.44	2.07	1.74–2.45
2	2.00	1.73–2.30	1.97	1.68–2.42	1.93	1.61–2.32	2.00	1.71–2.33
3	1.94	1.71–2.20	1.91	1.65–2.30	1.87	1.59–2.20	1.94	1.69–2.23
4	1.88	1.68–2.11	1.84	1.63–2.19	1.81	1.56–2.10	1.88	1.66–2.13
5	1.83	1.65–2.02	1.78	1.59–2.08	1.75	1.54–2.00	1.82	1.62–2.03
6	1.77	1.61–1.95	1.72	1.56–1.99	1.70	1.50–1.92	1.76	1.58–1.95
7	1.72	1.58–1.88	1.66	1.52–1.91	1.64	1.46–1.84	1.70	1.54–1.89
8	1.67	1.53–1.83	1.60	1.48–1.84	1.59	1.41–1.78	1.65	1.49–1.83
9	1.62	1.48–1.78	1.55	1.42–1.78	1.54	1.37–1.73	1.60	1.43–1.78
10	1.58	1.43–1.74	1.49	1.37–1.73	1.49	1.31–1.69	1.55	1.38–1.74
	<b><i>P</i> = 0.0035</b>		<b><i>P</i> = 0.0031</b>		<b><i>P</i> = 0.0095</b>		<b><i>P</i> = 0.0042</b>	

[4]. It is of interest that the quantum of effect was not dependent on the question construct. The size of the effect was also relatively immune to cohort quality and different races and ethnicities. Nonetheless, the true effect size relies on the accuracy of information provided which cannot be assessed in the construct of the present study. For the purposes of risk assessment, however, accuracy and causality of associations are of less concern than repeatability, and that the risk identified shows reversibility of effect [17, 26].

The extensive data resource permitted the elucidation of important interactions comprising an interaction with age and time since baseline. For all fracture outcomes, the risk ratios decreased significantly with age, consistent with our previous meta-analysis [4] and incorporated into FRAX [17]. Of importance, we were able to examine the risk associated with prior fractures among the oldest old. Additionally, the increased power of the present study revealed that hazard ratios also decreased significantly with time, a phenomenon not accounted for in the current FRAX model [17]. As with all risk variables used in FRAX, any interaction of effect over time is also important to incorporate in future probability models.


The present study also quantified the independent contributions of low BMD and prior fracture. For all outcomes studied, low BMD explained a minority of the total risk. The mechanism for the BMD-independent increase in risk could not be determined from this study but is likely due, in part, to coexisting morbidity that might increase the risk of falls or impair the protective responses to injury [26, 27]. In addition, changes in the structural or material properties of bone may weaken bone out of proportion to any effect on BMD [28–33].

A particular strength of the present study is that the estimate of risk is made in an international setting largely from population-based cohorts. Calculations were based on the primary data, decreasing the risk of publication biases. The consistency of the association between cohorts additionally indicates the international validity of this risk variable. The present study has several limitations that should be mentioned. As with nearly all population-based studies, nonresponse biases may have occurred, which we were unable to document for all cohorts. The effect is likely to exclude sicker members of society, including those in institutional care, and may underestimate the absolute

risk of fracture. Thus, the probability of a prior fracture may be underestimated from a societal perspective, but this is unlikely to affect risk ratios. The greatest potential problem was the construct of the question concerning prior fractures and the methods of documenting and characterizing subsequent fracture events. These differed substantially between cohorts. The effect of this heterogeneity on fracture outcomes was, however, marginal. It should also be recognized that additional factors affect the risk associated with a prior fracture. The increase in risk is more marked the greater the number of prior fractures [34–36], particularly prior vertebral fractures for a subsequent vertebral fracture [34, 37–40]. Also, the risk of a subsequent osteoporotic fracture is particularly acute immediately after an index fracture and wanes progressively with time [3, 41–43]. For example, after a fracture, the risk of subsequent fracture is highest in the immediate post fracture interval with more than one-third of subsequent fractures occurring within 1 year [44]. The waning of risk with time is also age dependent [43]. Also, the effect of recency is site dependent [45] with higher risk ratios for hip and vertebral fracture than for humerus, forearm, or minor osteoporotic fracture. Finally, morphometric but subclinical fractures were not assessed though they do add to fracture probability independently of FRAX [46]. Data on these additional modulating factors were not available for this meta-analysis; thus, residual confounding could be present in our findings. However, adjustments to FRAX probabilities for these factors are available through FRAXplus [47]. FRAXplus, which has recently been released in a beta version, brings together a number of adjustments that can illustrate the potential impact of modulating factors on FRAX fracture probabilities. These include trabecular bone score, recency of fracture (by site and time within the last 2 years), the number of self-reported falls in the previous year, glucocorticoid dose, and duration of type 2 diabetes mellitus. An additional limitation is that no account was taken of treatment effects.

In conclusion, this analysis has quantified the magnitude of the risk for future fractures conferred by a prior fracture in the largest meta-analysis conducted to date, and that this risk is largely independent of BMD. The effect is similar in men and women. The consistency of the association in an international setting provides the rationale for the use of these data in the next iteration of FRAX.

## Appendix



**Fig. 3** Forest plot showing effect size on osteoporotic fracture risk (left panel) and any clinical fracture (right panel) associated with a prior fracture in men and women combined adjusted for age and time since baseline

**Table 8** Hazard ratio (HR) and 95% confidence interval (CI) at the sites shown associated with a history of a prior fracture in men and women in those cohorts that contributed both men and women

Adjusted for BMD	Outcome fracture	Men			Women			Number of cohorts	<i>p</i> -value for interaction
		HR	95% CI		HR	95% CI			
No	Any	1.94	1.55	2.42	1.93	1.70	2.20	28	0.95
	Hip	1.94	1.44	2.61	1.73	1.46	2.05	22	0.21
	MOF	1.90	1.48	2.45	1.86	1.60	2.16	25	0.74
	Osteoporotic	1.95	1.54	2.46	1.87	1.63	2.14	25	0.53
Yes	Any	1.71	1.27	2.31	1.79	1.50	2.14	24	0.60
	Hip	1.75	1.14	2.69	1.53	1.16	2.02	15	0.25
	MOF	1.70	1.22	2.36	1.63	1.33	2.00	22	0.59
	Osteoporotic	1.68	1.23	2.31	1.71	1.42	2.07	23	0.84

MOF major osteoporotic fracture

**Table 9** Hazard ratio (HR) and 95% confidence interval (CI) of fracture at the sites indicated associated with a history of prior fracture in men and women according to race/ethnicity. HRs are adjusted for age and time since baseline

Outcome fracture	Number of cohorts	HR	95% CI	HR	95% CI	p-value
<b>Asian vs White</b>		<b>White</b>		<b>Asian</b>		
Any	5	1.77	1.51–2.09	1.73	1.29–2.32	0.84
Hip	3	1.64	1.45–1.85	1.97	0.86–4.51	0.66
MOF	5	1.77	1.52–2.06	1.79	1.12–2.86	0.95
<b>Black vs White</b>		<b>White</b>		<b>Black</b>		
Any	6	1.71	1.47–2.00	1.90	1.45–2.49	0.38
Hip	4	1.60	1.42–1.80	2.10	1.38–3.20	0.21
MOF	4	1.57	1.33–1.86	2.14	1.55–2.96	0.038
<b>Hispanic vs White</b>		<b>White</b>		<b>Hispanic</b>		
Any	2	1.47	1.39–1.56	1.29	0.84–1.98	0.55
Hip	2	1.53	1.39–1.67	1.96	0.84–4.58	0.56
MOF	2	1.49	1.40–1.60	1.72	1.05–2.82	0.57
<b>Other than White vs White</b>		<b>White</b>		<b>Other than White</b>		
Any	7	1.70	1.48–1.95	1.87	1.54–2.26	0.18
Hip	6	1.71	1.48–1.97	2.09	1.51–2.89	0.19
MOF	7	1.70	1.50–1.93	2.10	1.64–2.69	0.057

**Table 10** Hazard ratio (HR) and 95% confidence interval (CI) of fracture at the sites indicated associated with a history of prior fracture in men and women combined according to quality score. HRs are adjusted for age and time since baseline

	Outcome fracture	Number of cohorts	HR	95% CI	p <sup>a</sup>
<b>High quality</b>					
	Any	27	1.88	1.62–2.19	
	Hip	26	1.71	1.44–2.03	
	MOF	25	1.84	1.53–2.23	
	Osteoporotic	26	1.87	1.60–2.19	
<b>Moderate quality</b>					
	Any	31	1.81	1.67–1.95	0.66
	Hip	29	1.82	1.64–2.01	0.54
	MOF	29	1.71	1.59–1.85	0.89
	Osteoporotic	28	1.78	1.65–1.92	0.58
<b>Low quality</b>					
	Any	4	2.00	1.23–3.26	0.81
	Hip	1	1.36	0.86–2.14	0.36
	MOF	1	5.47	2.05–14.55	0.033
	Osteoporotic	2	2.63	0.75–9.16	0.60

<sup>a</sup>Two-sided *p*-values compared with high quality

**Acknowledgements** We are grateful to Dr. Östen Ljunggren for contributing the MrOS Sweden cohort. UK Biobank data are included under approved access agreement 3593. The authors acknowledge the Manitoba Centre for Health Policy for use of Manitoba data contained in the Population Health Research Data Repository (HIPC 2016/2017–29). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, Seniors and Active Living, or other data providers is intended or should be inferred.

**Funding** The WHI program is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services through 75N92021D00001, 75N92021D00002, 75N92021D00003, 75N92021D00004, and 75N92021D00005.

## Declarations

**Ethics approval** All individual cohorts with candidate risk factors available have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield. Participant data will be stored in coded, de-identified form. Only summary statistics and aggregate data will be published, not allowing for identification of individual study participants.

**Consent to participate** All individual cohorts with candidate risk factors available have been approved by their local ethics committees and informed consent has been obtained from all study participants. General ethics approval for the use of these cohorts is also given by the University of Sheffield.

**Conflict of interest** J.A. Kanis led the team that developed FRAX as director of the WHO Collaborating Centre for Metabolic Bone Diseases. E.V. McCloskey, W.D. Leslie, M. Lorentzon, N.C. Harvey, E. Liu, L. Vandenput, and H. Johansson are members of the FRAX team. J.A. Kanis, N.C. Harvey, and E.V. McCloskey are members of the advisory body to the National Osteoporosis Guideline Group. J.A. Kanis reports no additional competing interests. K.E. Åkesson has no financial interest related to FRAX; chaired the National SALAR Group for Person-Centered Care Pathway Osteoporosis. F.A. Anderson led the team that developed GLOW, while director of the Center for Outcomes Research at the University of Massachusetts Medical School; he has no financial interest in FRAX. R. Azagra has received funding for research from Instituto Carlos III of Spanish Ministry of Health, IDIAP Jordi Gol of Catalan Government, and from Scientific Societies SEMFYC and SEIOMM. C.L. Bager is employed at Nordic Bioscience and owns stock in Nordic Bioscience. She declares no competing interests in relation to this work. H.A. Bischoff-Ferrari has no financial interest in FRAX. For the DO-HEALTH trial cohort, Prof. Bischoff-Ferrari reports independent and investigator-initiated grants from European Commission Framework 7 Research Program, from the University of Zurich, from NESTEC, from Pfizer Consumer Healthcare, from Streuli Pharma, plus non-financial support from DNP. For the study cohort extension, she reports independent and investigator-initiated grants from Pfizer and from Vifor. Further, Prof. Bischoff-Ferrari reports non-financial support from Roche Diagnostics and personal fees from Wild, Sandoz, Pfizer, Vifor, Mylan, Roche, Meda Pharma, outside the submitted work with regard to speaker fees and travel fees. J.R. Center has received honoraria for speaking at educational meetings and for advisory boards from Amgen and honoraria for an advisory board from Bayer. R. Chapurlat has no financial interest in FRAX. He has received grant funding from Amgen, UCB, Chugai, MSD, Mylan and Medac. He has received honoraria from Amgen, UCB, Chugai, Galapagos, Biocon, Abbvie, Haoma Medica, Pfizer, Amolyt, MSD, Lilly, BMS, Novartis, Arrow, PKMed, Kyowa-Kirin, and Sanofi. C. Christiansen owns stock in Nordic Bioscience. He declares no competing interests in relation to this work. C. Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. A. Diez-Perez reports personal fees from Amgen, Lilly, Theramex and grants from Instituto Carlos III and owns shares of Active Life Scientific, all outside the submitted work. J.A. Eisman declares consulting and research support from Actavis, Amgen, Aspen, Lilly, Merck Sharp and Dohme, Novartis, Sanofi-Aventis, Servier, and Theramex. P.J.M. Elders has no financial interest in FRAX. P.J.M. Elders reports support for the SOS study by Stichting Achmea Gezondheidszorg, Achmea, and VGZ zorgverzekeraar. Additional support was given by the stichting Artsenlaboratorium en Trombosedienst. Outside the submitted work, she did receive independent investigator-driven grants by Zonmw, the Netherlands; de Hartstichting, the Netherlands; the European foundation for the study of Diabetes, Amgen, the Netherlands; TEVA, the Netherlands; and Takeda, the Netherlands. Claus-C. Glüer reports honoraria and research support from AgNovos, Amgen, Osteolabs, and UCB unrelated to this work. N.C. Harvey has received consultancy/lecture fees/honoraria/grant funding from Alliance for Better Bone Health, Amgen, MSD, Eli Lilly, Radius Health, Servier, Shire, UCB, Consilient Healthcare, and Internis Pharma. D.P. Kiel has no financial interest in FRAX but has received support for his work in the Framingham Study over the past 30 years by the National Institutes of Health, Astra Zeneca, Merck, Amgen, and Radius Health. MA Kotowicz has received funding from the National Health and Medical Research Council (NHMRC), Australia, and the Medical Research Future Fund (MRFF), Australia. He has served on advisory boards for Amgen Australia, Novartis, and Eli Lilly—all unrelated to this work, and is the Director of the Geelong Bone Densitometry Service. M. Lorentzon has received lecture fees from Amgen, Lilly, Meda, Renapharma, and UCB Pharma and consulting fees from Amgen, Radius Health, UCB Pharma, Renapharma, and Consilient Health, all outside the presented work.

E.V. McCloskey has received consultancy/lecture fees/grant funding/honoraria from AgNovos, Amgen, AstraZeneca, Consilient Healthcare, Fresenius Kabi, Gilead, GSK, Hologic, Internis, Lilly, Merck, Novartis, Pfizer, Radius Health, Redx Oncology, Roche, Sanofi Aventis, UCB, ViiV, Warner Chilcott, and I3 Innovus. C. Ohlsson is listed as a coinventor on two patent applications regarding probiotics in osteoporosis treatment. E.S. Orwoll reports consulting fees from Amgen, Biocon, Radius, and Bayer, and research support from Mereo. J.A. Pasco has received funding from the National Health and Medical Research Council (NHMRC), Australia, and the Medical Research Future Fund (MRFF), Australia, all unrelated to this work. K.M.A. Swart is an employee of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies. N.C. Wright sits on the Board of Trustee of the US Bone Health and Osteoporosis Foundation and has received consulting fees from Radius and ArgenX. M.C. Zillikens has received honoraria in the past for lectures or advice from Alexion, Amgen, Eli Lilly, Kyowa Kirin, Shire, and UCB, unrelated to the current work. M. Zwart has received research funding from national societies (SEMFYC and SEIOMM). C. Beaudart, E. Biver, O. Bruyère, J.A. Cauley, C.J. Crandall, S.R. Cummings, J.A.P. da Silva, B. Dawson-Huges, A.B. Dufour, S. Ferrari, Y. Fujita, S. Fujiwara, I. Goldshtein, D. Goltzman, V. Gudnason, J. Hall, D. Hans, M. Hoff, R.J. Hollick, M. Huisman, M. Iki, S. Ish-Shalom, H. Johansson, G. Jones, M.K. Karlsson, S. Khosla, W.-P. Koh, F. Koromani, H. Kröger, T. Kwok, O. Lamy, A. Langhammer, B. Larijani, W.D. Leslie, K. Lippuner, E. Liu, D. Mellström, T. Merlijn, A. Nordström, P. Nordström, T.W. O'Neill, B. Obermayer-Pietsch, F. Rivadeneira, A.-M. Schott, E.J. Shiroma, K. Siggeirsdottir, E.M. Simonsick, E. Sornay-Rendu, R. Sund, K.M.A. Swart, P. Szulc, J. Tamaki, D.J. Torgerson, L. Vandenput, N.M. van Schoor, T.P. van Staa, J. Vila, N.J. Wareham, and N. Yoshimura declare no competing interests in relation to this work.

## References

1. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. *J Bone Miner Res* 15:721–739
2. Haentjens P, Johnell O, Kanis JA, Bouillon R, Cooper C, Lamraski G, Vanderschuren D, Kauffman J-M, Boonen S (2004) Gender-related differences in short and long-term absolute risk of hip fracture after Colles' or spine fracture: Colles' fracture as an early and sensitive marker of skeletal fragility in men. *J Bone Miner Res* 19:1933–1944
3. Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Pettersen C, De Laet C, Jonsson B (2004) Fracture risk following an osteoporotic fracture. *Osteoporos Int* 15:175–179
4. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ III, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. *Bone* 35:375–382
5. Hansen L, Petersen KD, Eriksen SA, Langdahl BL, Eiken PA, Brixen K, Abrahamsen B, Jensen JE, Harslof T, Vestergaard P (2015) Subsequent fracture rates in a nationwide population-based cohort study with a 10-year perspective. *Osteoporos Int* 26:513–519
6. Crandall CJ, Hunt RP, LaCroix AZ, Robbins JA, Wactawski-Wende J, Johnson KC, Sattari M, Stone KL, Weitlauf JC, Gure TR, Cauley JA (2021) After the initial fracture in postmenopausal women, where do subsequent fractures occur? *EclinicalMedicine* 35:100826. <https://doi.org/10.1016/j.eclim.2021.100826>



7. Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV, The Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. *Arch Osteoporos* 11:25. <https://doi.org/10.1007/s11657-016-0278-z>
8. Kanis JA, Johansson H, Harvey NC, McCloskey EV, Lorentzon M, Liu E, Vandenput L, McCloskey EV • National Osteoporosis Guideline Group (2021) An assessment of intervention thresholds for very high risk applied to the NOGG guidelines. A report for the National Osteoporosis Guideline Group (NOGG). *Osteoporos Int* 32: 1951–1960
9. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD, Scientific Advisory Council of Osteoporosis Canada (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. *CMAJ* 182:1864–1873
10. Gregson CL, Armstrong DJ, Bowden J, Cooper C, Edwards J, Gittos NJL, Harvey N, Kanis J, Leyland S, Low R, McCloskey E, Moss K, Parker J, Paskins Z, Poole K, Reid DM, Stone M, Thomson J, Vine N, Compston J (2022) UK clinical guideline for the prevention and treatment of osteoporosis. *Arch Osteoporos* 17(1):58. <https://doi.org/10.1007/s11657-022-01061-5> Erratum in: *Arch Osteoporos*. 2022 May 19;17(1):80
11. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B Randall S, Lindsay R (2014) Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 25: 2359–2381.
12. Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. *Arch Osteoporos* 7:3–20. <https://doi.org/10.1007/s11657-012-0109-9>
13. Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos Int* 30:3–44
14. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 33:2049–2102 Erratum in: *Osteoporos Int*. 2022 Jul 28
15. Nguyen ND, Frost SA, Center JR, Eisman JA, Nguyen TV (2008) Development of prognostic nomograms for individualizing 5-year and 10-year fracture risks. *Osteoporos Int* 19:1431–1444
16. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of Qfracture Scores. *BMJ* 339:b4229
17. Kanis JA on behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary health-care level. WHO Collaborating Centre, University of Sheffield, UK, Technical Report Available at <http://www.shef.ac.uk/FRAX/index.htm>. Accessed 17 Jan 2023
18. Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. CHMP, London
19. National Institute for Health and Care Excellence (2012) NICE clinical guideline 146. In: Osteoporosis: assessing the risk of fragility fracture, London, UK <https://www.nice.org.uk/guidance/cg146>. Accessed 2 June 2022
20. Vandenput L, Johansson H, McCloskey EV et al (2022) Update of the fracture risk prediction tool FRAX: a systematic review of potential cohorts and analysis plan. *Osteoporos Int* 33:2103–2136. <https://doi.org/10.1007/s00198-022-06435-6>
21. Kanis JA, Oden A, Johnell O, Jonsson B, De Laet C, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. *Osteoporos Int* 12:417–427
22. Leslie WD, Schousboe JT, Morin SN, Martineau P, Lix JM, Johansson H, McCloskey EV, Harvey NC, Kanis JA (2020) Fracture risk following high-trauma versus non-trauma fracture: a registry-based cohort study. *Osteoporos Int* 31:1059–1067
23. Breslow NE, Day NE (1987) Statistical methods in cancer research, 2 IARC Scientific Publications. Lyon 32:131–135
24. Albertsson-Wikland K, Martensson A, Niklasson SLA, Bang P, Martensson A, Dahlgren J, Gustafsson J, Kristrom B, Norgren S, Pehrsson NG, Oden A (2016) Mortality is not increased in recombinant human growth hormone-treated patients when adjusting for birth characteristics. *J Clin Endocrinol Metab* 101:2149–2159
25. Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier PJ, Melton LJ III, O'Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of BMD for hip and other fractures. *J Bone Miner Res* 20:1185–1194
26. Kline GA, Morin SN, Lix LM, McCloskey EV, Johansson H, Harvey NC, Kanis JA, Leslie WD (2022) General comorbidity indicators contribute to fracture risk independent of FRAX: registry-based cohort study. *J Clin Endocrinol Metab*:dgac582. <https://doi.org/10.1210/clinem/dgac582> Epub ahead of print
27. Ensrud KE, Nevitt MC, Yunis C, Cauley JA, Seeley DG, Fox KM, Cummings SR (1994) Correlates of impaired function in older women. *J Am Geriatr Soc* 42:481–489
28. Silva BC, Leslie WD, Resch H, Lamy O, Lesnyak O, Binkley N, McCloskey EV, Kanis JA, Bilezikian JP (2014) Trabecular bone score: a noninvasive analytical method based upon the DXA image. *J Bone Miner Res* 29:518–530. <https://doi.org/10.1002/jbmr.2176> Erratum in: *J Bone Miner Res* 2017 Nov;32(11):2319
29. Harvey NC, Gluer CC, Binkley N, McCloskey EV, Brandi M-L, Cooper C, Kendler D, Lamy O, Laslop A, Camargos B, Reginster J-Y, Rizzoli R, Kanis JA (2015) Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. A consensus report of a European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Working Group. *Bone* 78:216–224
30. Samelson EJ, Broe KE, Xu H, Yang L, Boyd S, Biver E, Szulc P, Adachi J, Amin S, Atkinson E, Berger C, Burt L, Chapurlat R, Chevalley T, Ferrari S, Goltzman D, Hanley DA, Hannan MT, Khosla S et al (2019) Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. *Lancet Diabetes Endocrinol* 7(1):34–43. [https://doi.org/10.1016/S2213-8587\(18\)30308-5](https://doi.org/10.1016/S2213-8587(18)30308-5) Erratum in: *Lancet Diabetes Endocrinol*. 2019 Jan;7(1):e1. Erratum in: *Lancet Diabetes Endocrinol*. 2019 Jun;7(6):e18
31. Dempster DW 92000 The contribution of trabecular architecture to cancellous bone quality. *J Bone Miner Res* 15:20–23
32. Vignat-Carrin S, Garnero P, Delmas PD (2006) The role of collagen in bone strength. *Osteoporos Int* 17:319–336
33. Burr DB (2019) Changes in bone matrix properties with aging. *Bone* 120:85–93. <https://doi.org/10.1016/j.bone.2018.10.010>
34. Gallagher JC, Genant HK, Crans GG, Vargas SJ, Klege JH (2005) Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. *J Clin Endocrinol Metab* 90:1583–1587
35. Agarwal A, Leslie WD, Nguyen TV, Morin SN, Lix LM, Eisman JA (2022) Predictive performance of the Garvan Fracture Risk Calculator: a registry-based cohort study. *Osteoporos Int* 33:541–548



36. Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu E, Vandenput L, McCloskey EV (2022) Adjusting conventional FRAX estimates of fracture probability according to the number of prior fractures. *Osteoporos Int* 33:2507–2515
37. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. *J Bone Miner Res* 14:821–828
38. Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH (2007) Enhanced prediction of fracture risk combining vertebral fracture status and BMD. *Osteoporos Int* 18:761–770
39. Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. *Bone* 33:522–532
40. Lunt M, O'Neill TW, Felsenberg D, Reeve J, Kanis JA, Cooper C, Silman AJ, European Prospective Osteoporosis Study Group (2003) Characteristics of a prevalent vertebral deformity predict subsequent vertebral fracture: results from the European Prospective Osteoporosis Study (EPOS). *Bone* 33:505–513
41. Johnell O, Oden A, Caulin F, Kanis JA (2001) Acute and long-term increase in fracture risk after hospitalization for vertebral fracture. *Osteoporos Int* 12:207–214
42. Giangregorio LM, Leslie WD (2010) Manitoba bone density program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures. *J Bone Miner Res* 25:1400–1405
43. Nymark T, Lauritsen JM, Ovesen O, Rock ND, Jeune B (2006) Short timeframe from first to second hip fracture in the Funen County Hip Fracture Study. *Osteoporos Int* 17:1353–1357
44. Kanis JA, Johansson H, Odén A, Harvey NC, Gudnason V, Sanders K, Sigurdsson G, Siggeirsdottir K, Borgström F, McCloskey EV (2018) Characteristics of recurrent fractures. *Osteoporos Int* 29:1747–1757
45. Kanis JA, Johansson H, Harvey NC, Gudnason V, Sigurdsson G, Siggeirsdottir K, Lorentzon M, Liu M, Vandenput L, McCloskey E (2021) The effect on subsequent fracture risk of age, sex and prior fracture site by recency of prior fracture. *Osteoporos Int* 32:1547–1555
46. Johansson L, Johansson H, Harvey NC, Liu E, Vandenput L, McCloskey E, Kanis JA, Lorentzon M (2021) Improved fracture risk prediction by adding VFA-identified vertebral fracture data to BMD by DXA and clinical risk factors used in FRAX. *Osteoporos Int* 33:1725–1738
47. McCloskey EV (2013) FRAXplus – post hoc exploration of impact of additional risk factor information on FRAX probability calculations. *Aging Clin Exp Res* 35 (Suppl 1) in press
48. Kanis JA, McCloskey E, Johansson H, Oden A, Leslie WD (2012) FRAX(®) with and without bone mineral density. *Calcif Tissue Int* 90:1–13
49. Johansson H, Siggeirsdottir K, Harvey NC, Odén A, Gudnason V, McCloskey E, Sigurdsson G, Kanis JA (2017) Imminent risk of fracture after fracture. *Osteoporos Int* 28:775–780

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

## Authors and Affiliations

J.A. Kanis<sup>1,2</sup> · H. Johansson<sup>1,3</sup> · E.V. McCloskey<sup>2,4</sup> · E. Liu<sup>1</sup> · K.E. Åkesson<sup>5,6</sup> · F.A. Anderson<sup>7</sup> · R. Azagra<sup>8,9,10</sup> · C.L. Bager<sup>11</sup> · C. Beaudart<sup>12,13</sup> · H.A. Bischoff-Ferrari<sup>14,15</sup> · E. Biver<sup>16</sup> · O. Bruyère<sup>12</sup> · J.A. Cauley<sup>17</sup> · J.R. Center<sup>18,19,20</sup> · R. Chapurlat<sup>21</sup> · C. Christiansen<sup>11</sup> · C. Cooper<sup>22,23,24</sup> · C.J. Crandall<sup>25</sup> · S.R. Cummings<sup>26</sup> · J.A.P. da Silva<sup>27,28</sup> · B. Dawson-Hughes<sup>29</sup> · A. Diez-Perez<sup>30</sup> · A.B. Dufour<sup>31,32</sup> · J.A. Eisman<sup>18,19,20</sup> · P.J.M. Elders<sup>33</sup> · S. Ferrari<sup>16</sup> · Y. Fujita<sup>34</sup> · S. Fujiwara<sup>35</sup> · C.-C. Glüer<sup>36</sup> · I. Goldshtein<sup>37,38</sup> · D. Goltzman<sup>39</sup> · V. Gudnason<sup>40,41</sup> · J. Hall<sup>42</sup> · D. Hans<sup>43</sup> · M. Hoff<sup>44,45</sup> · R.J. Hollick<sup>46</sup> · M. Huisman<sup>47,48</sup> · M. Iki<sup>49</sup> · S. Ish-Shalom<sup>50</sup> · G. Jones<sup>51</sup> · M.K. Karlsson<sup>5,6</sup> · S. Khosla<sup>52</sup> · D.P. Kiel<sup>31,32</sup> · W.-P. Koh<sup>53,54</sup> · F. Koromani<sup>55,56</sup> · M.A. Kotowicz<sup>57,58,59</sup> · H. Kröger<sup>60,61</sup> · T. Kwok<sup>62,63</sup> · O. Lamy<sup>64,65</sup> · A. Langhammer<sup>66</sup> · B. Larijani<sup>67</sup> · K. Lippuner<sup>68</sup> · D. Mellström<sup>69,70</sup> · T. Merlijn<sup>71</sup> · A. Nordström<sup>72,73,74</sup> · P. Nordström<sup>75</sup> · T.W. O'Neill<sup>76,77</sup> · B. Obermayer-Pietsch<sup>78,79</sup> · C. Ohlsson<sup>80,81</sup> · E.S. Orwoll<sup>82</sup> · J.A. Pasco<sup>57,58,59,83</sup> · F. Rivadeneira<sup>55</sup> · A.-M. Schott<sup>84</sup> · E.J. Shiroma<sup>85</sup> · K. Siggeirsdottir<sup>40,86</sup> · E.M. Simonsick<sup>87</sup> · E. Sornay-Rendu<sup>88</sup> · R. Sund<sup>61</sup> · K.M.A. Swart<sup>33,89</sup> · P. Szulc<sup>88</sup> · J. Tamaki<sup>90</sup> · D.J. Torgerson<sup>91</sup> · N.M. van Schoor<sup>47</sup> · T.P. van Staa<sup>92</sup> · J. Vila<sup>93</sup> · N.J. Wareham<sup>94</sup> · N.C. Wright<sup>95</sup> · N. Yoshimura<sup>96</sup> · M.C. Zillikens<sup>55</sup> · M. Zwart<sup>10,97,98,99</sup> · L. Vandenput<sup>1,80</sup> · N.C. Harvey<sup>22,23</sup> · M. Lorentzon<sup>1,3</sup> · W.D. Leslie<sup>100</sup>

✉ J.A. Kanis  
w.j.pontefract@sheffield.ac.uk

H. Johansson  
helena@statiq.se

E.V. McCloskey  
e.v.mccloskey@sheffield.ac.uk

E. Liu  
enwu.liu@acu.edu.au

K.E. Åkesson  
kristina.akesson@med.lu.se

F.A. Anderson  
fred.anderson@umassmed.edu

R. Azagra  
rafael.azagra@uab.cat

C.L. Bager  
cba@nordicbio.com

C. Beaudart  
c.beaudart@maastrichtuniversity.nl

H.A. Bischoff-Ferrari  
heike.bischoff@usz.ch

E. Biver  
emmanuel.biver@hcuge.ch

O. Bruyère  
olivier.bruyere@uliege.be

J.A. Cauley  
jcauley@edc.pitt.edu

J.R. Center  
j.center@garvan.org.au

R. Chapurlat  
roland.chapurlat@inserm.fr

C. Christiansen  
cc@nordicbio.com

C. Cooper  
cc@mrc.soton.ac.uk

C.J. Crandall  
ccrandall@mednet.ucla.edu

S.R. Cummings  
steven.cummings@ucsf.edu

J.A.P. da Silva  
jdasilva@ci.uc.pt

B. Dawson-Hughes  
bess.dawson-hughes@tufts.edu

A. Diez-Perez  
adiez@psmar.cat

A.B. Dufour  
alyssadufour@hsl.harvard.edu

J.A. Eisman  
j.eisman@garvan.org.au

P.J.M. Elders  
p.elders@amsterdamumc.nl

S. Ferrari  
serge.ferrari@unige.ch

Y. Fujita  
yfujita@med.kindai.ac.jp

S. Fujiwara  
fujiwara-s@yasuda-u.ac.jp

C.-C. Glüer  
glueer@rad.uni-kiel.de

I. Goldshtein  
inbalbarak@gmail.com

D. Goltzman  
david.goltzman@mcgill.ca

V. Gudnason  
v.gudnason@hjarta.is

J. Hall  
jill.hall@ed.ac.uk

D. Hans  
didier.hans@chuv.ch

M. Hoff  
mari.hoff@ntnu.no

R.J. Hollick  
rhollick@abdn.ac.uk

M. Huisman  
m.huisman@amsterdamumc.nl

M. Iki  
masa@med.kindai.ac.jp

S. Ish-Shalom  
sishshalom@gmail.com

G. Jones  
g.jones@utas.edu.au

M.K. Karlsson  
magnus.karlsson@med.lu.se

S. Khosla  
khosla.sundeep@mayo.edu

D.P. Kiel  
kiel@hsl.harvard.edu

W.-P. Koh  
kohwp@nus.edu.sg

F. Koromani  
f.koromani@erasmusmc.nl

M.A. Kotowicz  
mark.kotowicz@deakin.edu.au

H. Kröger  
heikki.kroger@kuh.fi

T. Kwok  
tkwok@cuhk.edu.hk

O. Lamy  
olivier.lamy@chuv.ch

A. Langhammer  
arnulf.langhammer@ntnu.no

B. Larijani  
emrc@tums.ac.ir

K. Lippuner  
kurt.lippuner@insel.ch

D. Mellström  
dan.mellstrom@vgregion.se

T. Merlijn  
tmerlijn@gmail.com

A. Nordström  
anna.h.nordstrom@umu.se

P. Nordström  
peter.nordstrom@umu.se

T.W. O'Neill  
terence.o'neill@manchester.ac.uk

B. Obermayer-Pietsch  
barbara.obermayer@medunigraz.at

C. Ohlsson  
claes.ohlsson@medic.gu.se

J.A. Pasco  
julie.pasco@deakin.edu.au

F. Rivadeneira  
f.rivadeneira@erasmusmc.nl

A.-M. Schott  
anne-marie.schott@inserm.fr

E.J. Shiroma  
eric.shiroma@nih.gov

K. Siggeirsdottir  
kristin@janus.is

E.M. Simonsick  
simonsickel@grc.nia.nih.gov

E. Sornay-Rendu  
elisabeth.rendu@inserm.fr

R. Sund  
reijo.sund@uef.fi

K.M.A. Swart  
karin.swart-polinder@pharmo.nl

P. Szulc  
pawel.szulc@inserm.fr

J. Tamaki  
jtamaki@ompu.ac.jp

D.J. Torgerson  
david.torgerson@york.ac.uk

N.M. van Schoor  
nm.vanschoor@amsterdamumc.nl

T.P. van Staa  
tjeerd.vanstaa@manchester.ac.uk

J. Vila  
jvila@imim.es

N.J. Wareham  
nick.wareham@mrc-epid.cam.ac.uk

N.C. Wright  
ncwright@uab.edu

N. Yoshimura  
noripu@rc4.so-net.ne.jp

M.C. Zillikens  
m.c.zillikens@erasmusmc.nl

M. Zwart  
marta.zwart@udg.edu

L. Vandenput  
liesbeth.vandenput@acu.edu.au

N.C. Harvey  
nch@mrc.soton.ac.uk

M. Lorentzon  
mattias.lorentzon@medic.gu.se

W.D. Leslie  
bleslie@sbgh.mb.ca

<sup>2</sup> Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

<sup>3</sup> Sahlgrenska Osteoporosis Centre, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

<sup>4</sup> MRC Versus Arthritis Centre for Integrated research in Musculoskeletal Ageing, Mellanby Centre for Musculoskeletal Research, University of Sheffield, Sheffield, UK

<sup>5</sup> Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences, Lund University, Lund, Sweden

<sup>6</sup> Department of Orthopedics, Skåne University Hospital, Malmö, Sweden

<sup>7</sup> GLOW Coordinating Center, Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA

<sup>8</sup> Department of Medicine, Autonomous University of Barcelona, Barcelona, Spain

<sup>9</sup> Health Centre Badia del Valles, Catalan Institute of Health, Barcelona, Spain

<sup>10</sup> PRECIOSA-Fundación para la investigación, Barberà del Vallés, Barcelona, Spain

<sup>11</sup> Nordic Bioscience A/S, Herlev, Denmark

<sup>12</sup> WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium

<sup>13</sup> Department of Health Services Research, University of Maastricht, Maastricht, the Netherlands

<sup>14</sup> Department of Aging Medicine and Aging Research, University Hospital, Zurich, and University of Zurich, Zurich, Switzerland

<sup>15</sup> Centre on Aging and Mobility, University of Zurich and City Hospital, Zurich, Switzerland

<sup>16</sup> Division of Bone Diseases, Department of Medicine, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland

<sup>17</sup> Department of Epidemiology, School of Public Health, University of Pittsburgh, Pittsburgh, Philadelphia, USA

<sup>18</sup> Skeletal Diseases Program, Garvan Institute of Medical Research, Sydney, NSW, Australia

<sup>19</sup> St Vincent's Clinical School, School of Medicine and Health, University of New South Wales Sydney, Sydney, NSW, Australia

<sup>20</sup> School of Medicine Sydney, University of Notre Dame Australia, Sydney, NSW, Australia

<sup>21</sup> INSERM UMR 1033, Université Claude Bernard-Lyon1, Hôpital Edouard Herriot, Lyon, France

<sup>22</sup> MRC Lifecourse Epidemiology Centre, University of Southampton, Southampton, UK

<sup>23</sup> NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospitals Southampton NHS Foundation Trust, Southampton, UK

<sup>1</sup> Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia

- 24 NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK
- 25 Division of General Internal Medicine and Health Services Research, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
- 26 San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA, USA
- 27 Coimbra Institute for Clinical and Biomedical Research, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 28 Rheumatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
- 29 Bone Metabolism Laboratory, Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
- 30 Department of Internal Medicine, Hospital del Mar and CIBERFES, Autonomous University of Barcelona, Barcelona, Spain
- 31 Marcus Institute for Aging Research, Hebrew Senior Life, Boston, MA, USA
- 32 Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA
- 33 Petra JM Elders Department of General Practice, Amsterdam UMC, location AMC, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
- 34 Center for Medical Education and Clinical Training, Kindai University Faculty of Medicine, Osaka, Japan
- 35 Department of Pharmacy, Yasuda Women's University, Hiroshima, Japan
- 36 Section Biomedical Imaging, Molecular Imaging North Competence Center, Department of Radiology and Neuroradiology, University Medical Center Schleswig-Holstein Kiel, Kiel University, Kiel, Germany
- 37 Maccabitech Institute of Research and Innovation, Maccabi Healthcare Services, Tel Aviv, Israel
- 38 Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- 39 Department of Medicine, McGill University and McGill University Health Centre, Montreal, Canada
- 40 Icelandic Heart Association, Kopavogur, Iceland
- 41 University of Iceland, Reykjavik, Iceland
- 42 MRC Centre for Reproductive Health, University of Edinburgh, Edinburgh, UK
- 43 Interdisciplinary Centre of Bone Diseases, Bone and Joint Department, Lausanne University Hospital (CHUV) & University of Lausanne, Lausanne, Switzerland
- 44 Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
- 45 Department of Rheumatology, St Olavs Hospital, Trondheim, Norway
- 46 Aberdeen Centre for Arthritis and Musculoskeletal Health, Epidemiology Group, University of Aberdeen, Aberdeen, UK
- 47 Department of Epidemiology and Data Science, Amsterdam Public Health Research Institute, VU University Medical Center, Amsterdam, The Netherlands
- 48 Department of Sociology, VU University, Amsterdam, The Netherlands
- 49 Department of Public Health, Kindai University Faculty of Medicine, Osaka, Japan
- 50 Endocrine Clinic, Elisha Hospital, Haifa, Israel
- 51 Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia
- 52 Robert and Arlene Kogod Center on Aging and Division of Endocrinology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA
- 53 Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore
- 54 Singapore Institute for Clinical Sciences, Agency for Science Technology and Research (A\*STAR), Singapore, Singapore
- 55 Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- 56 Department of Radiology and Nuclear Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands
- 57 IMPACT (Institute for Mental and Physical Health and Clinical Translation), Deakin University, Geelong, Victoria, Australia
- 58 Barwon Health, Geelong, Victoria, Australia
- 59 Department of Medicine -Western Health, The University of Melbourne, St Albans, Victoria, Australia
- 60 Department of Orthopedics and Traumatology, Kuopio University Hospital, Kuopio, Finland
- 61 Kuopio Musculoskeletal Research Unit, University of Eastern Finland, Kuopio, Finland
- 62 Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong
- 63 Jockey Club Centre for Osteoporosis Care and Control, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, Hong Kong
- 64 Centre of Bone Diseases, Lausanne University Hospital, Lausanne, Switzerland
- 65 Service of Internal Medicine, Lausanne University Hospital, Lausanne, Switzerland
- 66 HUNT Research Centre, Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
- 67 Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
- 68 Department of Osteoporosis, Bern University Hospital, University of Bern, Bern, Switzerland
- 69 Geriatric Medicine, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

- <sup>70</sup> Geriatric Medicine, Sahlgrenska University Hospital Mölndal, Mölndal, Sweden
- <sup>71</sup> Department of General Practice, Amsterdam UMC, location AMC, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands
- <sup>72</sup> School of Sport Sciences, UiT The Arctic University of Norway, Tromsø, Norway
- <sup>73</sup> Department of Health Sciences, Swedish Winter Sports Research Centre, Mid Sweden University, Östersund, Sweden
- <sup>74</sup> Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- <sup>75</sup> Department of Public Health and Caring Sciences, Uppsala University, Uppsala, Sweden
- <sup>76</sup> National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
- <sup>77</sup> Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK
- <sup>78</sup> Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University Graz, Graz, Austria
- <sup>79</sup> Center for Biomarker Research in Medicine, Graz, Austria
- <sup>80</sup> Sahlgrenska Osteoporosis Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- <sup>81</sup> Department of Drug Treatment, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden
- <sup>82</sup> Department of Medicine, Oregon Health and Science University, Portland, OR, USA
- <sup>83</sup> Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia
- <sup>84</sup> Université Claude Bernard Lyon 1, U INSERM 1290 RESHAPE, Lyon, France
- <sup>85</sup> Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Baltimore, MD, USA
- <sup>86</sup> Janus Rehabilitation, Reykjavik, Iceland
- <sup>87</sup> Translational Gerontology Branch, National Institute on Aging Intramural Research Program, Baltimore, MD, USA
- <sup>88</sup> INSERM UMR 1033, University of Lyon, Hôpital Edouard Herriot, Lyon, France
- <sup>89</sup> PHARMO Institute for Drug Outcomes Research, Utrecht, The Netherlands
- <sup>90</sup> Department of Hygiene and Public Health, Faculty of Medicine, Educational Foundation of Osaka Medical and Pharmaceutical University, Osaka, Japan
- <sup>91</sup> York Trials Unit, Department of Health Sciences, University of York, York, UK
- <sup>92</sup> Centre for Health Informatics, Faculty of Biology, Medicine and Health, School of Health Sciences, University of Manchester, Manchester, UK
- <sup>93</sup> Statistics Support Unit, Hospital del Mar Medical Research Institute, CIBER Epidemiology and Public Health (CIBERESP), Barcelona, Spain
- <sup>94</sup> MRC Epidemiology Unit, University of Cambridge, Cambridge, UK
- <sup>95</sup> Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA
- <sup>96</sup> Department of Preventive Medicine for Locomotive Organ Disorders, The University of Tokyo Hospital, Tokyo, Japan
- <sup>97</sup> Health Center Can Gibert del Plà, Catalan Institute of Health, Girona, Spain
- <sup>98</sup> Department of Medical Sciences, University of Girona, Girona, Spain
- <sup>99</sup> GROIMAP/GROICAP (research groups), Unitat de Suport a la Recerca Girona, Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Girona, Spain
- <sup>100</sup> Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada